Trial Profile
Prospective Longitudinal Study on Immunogenicity, Induction of Cellular Immune Responses and Safety of Vaccination Against HPV With the 9-valent Vaccine in HIV-positive Women (The Papillon Study)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs V 503 (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- Acronyms Papillon; the Papillon Study
- 06 Feb 2024 Planned End Date changed from 2 May 2023 to 2 May 2026.
- 19 Jul 2022 Planned End Date changed from 8 Jan 2023 to 2 May 2023.
- 19 Jul 2022 Planned primary completion date changed from 1 Nov 2021 to 2 May 2023.